Physician profile
Jonathan D Bui
NPI 1730247974
$3,018.45
in general payments reported to CMS, 2019-2025
23 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $378 · 2021: $224 · 2022: $0.83 · 2023: $95.61 · 2024: $494 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.64 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $937.98 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $396.31 | 2024-2025 | |
| Ucb, INC. | $251.91 | 2024-2025 | Briviact, Fintepla |
| Mallinckrodt Enterprises LLC | $245.33 | 2019 | |
| Eisai INC. | $210.88 | 2019-2021 | |
| Neurelis, INC. | $149.92 | 2021-2024 | Valtoco |
| Greenwich Biosciences, INC. | $130.61 | 2019 | |
| Beigene USA, INC. | $115.38 | 2024 | Brukinsa |
| Supernus Pharmaceuticals, INC. | $92.18 | 2019-2021 | |
| Csl Behring | $88.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.61 | 2019-2020 | |
| Sk Life Science, INC. | $54.72 | 2021 | |
| Mallinckrodt Hospital Products INC. | $50.24 | 2020 | |
| Aquestive Therapeutics, INC. | $45.96 | 2019-2020 | |
| Lilly USA, LLC | $31.20 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $23.11 | 2023 | Viltepso |
| Alexion Pharmaceuticals, INC. | $22.84 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.86 | 2023 | Fycompa |
| Travere Therapeutics, INC. | $18.96 | 2021-2023 | Cholbam |
| Kaleo, INC. | $16.85 | 2019 | |
| Novo Nordisk INC | $16.83 | 2025 | Wegovy |
| Genentech USA, INC. | $14.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.